Medpace price target raised to $450 from $300 at Barclays

Barclays analyst Luke Sergott raised the firm’s price target on Medpace (MEDP) to $450 from $300 and keeps an Equal Weight rating on the shares. The firm says the biggest question going forward is whether the company’s strong Q2 bookings environment is sustainable to offset elevated burn-rates.